{"status": "Ok", "redirect_url": "https://www.prnewswire.com//news-releases/ideaya-biosciences-and-servier-provide-complete-data-from-phase-23-registrational-optimum-02-trial-of-the-darovasertib-combination-in-first-line-hlaa201-negative-metastatic-uveal-melanoma-in-a-late-breaking-oral-presentation-at-302786486.html", "message": "News view counter 770193 successfully enlarged"}